<DOC>
	<DOCNO>NCT00669227</DOCNO>
	<brief_summary>Autologous stem cell may improve myocardial regeneration intracoronary administration patient acute myocardial infarction . The primary hypothesis prospective , placebo-controlled , double-blind trial increase ejection fraction determine magnetic resonance image baseline 6 month follow-up superior active treat patient compare patient receive placebo . The study include integrate pilot phase 40 patient evaluation leave ventricular ejection fraction determine cardiac magnetic resonance imaging . Based data analysis final sample size calculate . The primary endpoint improvement leave ventricular ejection fraction assume 2.5 % high improvement cell treat population compare placebo treat group .</brief_summary>
	<brief_title>Intracoronary Stem Cell Therapy Patients With Acute Myocardial Infarction ( SCAMI )</brief_title>
	<detailed_description>There 2:1 randomization bone marrow cell therapy versus placebo therapy . Patients stratify accord age , localization myocardial infarction leave ventricular function .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>acute myocardial infarction time revascularization &gt; 6 hour symptom start clear target vessel large myocardial infarction define : proximal vessel occlusion , CK &gt; 1000 U/L , myocardial scar magnetic resonance image &gt; 10 % leave ventricular muscle mass potential prior thrombolysis write informed consent acute myocardial infarction revascularization within 6 hour symptom start prior myocardial infarction clear target vessel contraindication magnetic resonance imaging ( e.g . pacemaker , ICD ) severely depressed leave ventricular ejection fraction ( le 20 % magnetic resonance imaging ) prior hematologic disease prior chemo therapy prior stem cell transplantation prior treatment GCSF know alteration bone marrow alcohol drug , e.g . agranulocytosis local infection puncture site</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>